Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Viemed Healthcare (VMD) over the last 8 years, with Q3 2025 value amounting to $2.2 million.

  • Viemed Healthcare's Share-based Compensation rose 2733.64% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year increase of 3262.94%. This contributed to the annual value of $6.3 million for FY2024, which is 745.43% up from last year.
  • As of Q3 2025, Viemed Healthcare's Share-based Compensation stood at $2.2 million, which was up 2733.64% from $2.3 million recorded in Q2 2025.
  • Viemed Healthcare's Share-based Compensation's 5-year high stood at $2.3 million during Q2 2025, with a 5-year trough of $1.2 million in Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $1.4 million (2024), whereas its average is $1.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 84.75% in 2024, then surged by 6138.27% in 2025.
  • Viemed Healthcare's Share-based Compensation (Quarter) stood at $1.3 million in 2021, then rose by 0.92% to $1.3 million in 2022, then grew by 16.48% to $1.5 million in 2023, then fell by 0.85% to $1.5 million in 2024, then surged by 43.33% to $2.2 million in 2025.
  • Its Share-based Compensation stands at $2.2 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.3 million for Q1 2025.